Search research articles
Contact Us
Filters
Showing results (211-220 of 229) with videos related to
Page
of 23
Sort By:
Clinical and Translational Radiation Oncology
|
September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Investigational New Drugs
|
August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs
|
January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
BMC Nephrology
|
June 6, 2023
Development and nationwide validation of kidney graft injury markers using urinary exosomes and microvesicles (complete English translation of the Japanese version)
Hiroshi Harada, Nobuyuki Fukuzawa, Toyofumi Abe, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Investigational New Drugs
|
December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Lung Cancer
|
August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study
Asuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 229) with videos related to
Sort By:
Page
of 23
Clinical and Translational Radiation Oncology
|
September 6, 2022
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, et al.
Investigational New Drugs
|
August 9, 2019
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, et al.
Investigational New Drugs
|
January 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki, et al.
BMC Nephrology
|
June 6, 2023
Development and nationwide validation of kidney graft injury markers using urinary exosomes and microvesicles (complete English translation of the Japanese version)
Hiroshi Harada, Nobuyuki Fukuzawa, Toyofumi Abe, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 9, 2025
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, et al.
Investigational New Drugs
|
December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Lung Cancer
|
August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Clinical Lung Cancer
|
March 2, 2020
Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
Yuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 25, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study
Asuka Okada, Yoshihiko Sakata, Yuko Oya, et al.
Page
of 23